Snipr Biome, the Copenhagen company pioneering the development of microbial CRISPR-medicine, announced the close of a €35 million Series B fund raise.

The deal involves funding from new investors the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D) as well as existing investors Lundbeckfonden BioCapital, North-East Family Office and Wellington Partners.

“This funding will support the development of a CRISPR-Cas therapy specifically targeting airway infections caused by Pseudomonas aeruginosa in people with cystic fibrosis (CF),” said Snipr Biome.

“Additionally, it will enable the advancement of a CRISPR-based microbial intervention designed to eliminate antibiotic resistance genes in humans across various bacterial species and environments.

“The funding will also further the clinical development of the company’s CRISPR-based product, SNIPR001, in patients with hematologic cancer, including the ongoing phase 1b trial.”

Christian Grøndahl, CEO and Co-Founder of Snipr Biome, said: “This financing marks a pivotal milestone for Snipr Biome as we advance the clinical development of SNIPR001 for the prevention of blood stream infections and continue to expand our infectious disease pipeline targeting pathogens of critical importance.

“This support shows the importance of addressing antimicrobial resistance and infectious disease and the unique position of Snipr Biome in the development landscape.”

Snipr Biome is pioneering a novel use of CRISPR-Cas technology to cause selective, precise and ultra-rapid killing to eradicate target bacteria and remove the antibiotic resistance genes, while leaving the rest of the patient’s microbial community intact.